ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition |
On May 18, 2017 we issued a press release announcing the
announced that we completed enrollment and initiated dosing in a
second Phase 1 human pharmacokinetic trial of LTX-04, our lead
development candidate utilizing our LIMITx technology. A copy of
our press release is being filed as Exhibit 99.1 hereto.
| Item 9.01 | Financial Statements and Exhibits |
| Exhibit Number | Description |
| 99.1 | Press Release dated May 18, 2017 |
About ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR)
Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine. ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Recent Trading Information
ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) closed its last trading session down -0.017 at 0.503 with 513,075 shares trading hands.
